Manuela Rizzo

Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial

Antonio Palumbo, Davide Rossi, Maide Cavalli et al. · Journal of Clinical Oncology · 2010 · 424 citations · Full text

Toward Optimization of Postremission Therapy for Residual Disease–Positive Patients With Acute Myeloid Leukemia

Luca Maurillo, Francesco Buccisano, Maria Ilaria Del Principe et al. · Journal of Clinical Oncology · 2008 · 174 citations · Full text

Early Autologous Stem-Cell Transplantation Versus Conventional Chemotherapy as Front-Line Therapy in High-Risk, Aggressive Non-Hodgkin’s Lymphoma: An Italian Multicenter Randomized Trial

Maurizio Martelli, Filíppo Gherlinzoni, Amalia De Renzo et al. · Journal of Clinical Oncology · 2003 · 130 citations

Melphalan 200 mg/m2 versus melphalan 100 mg/m2 in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study

Antonio Palumbo, Sara Bringhen, Benedetto Bruno et al. · Blood · 2009 · 92 citations · Full text

Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial

Ilaria Saltarella, Fortunato Morabito, Nicola Giuliani et al. · Journal of Hematology & Oncology · 2019 · 58 citations · Full text